The Trump administration’s Labor Department finalized a rule Oct. 29 requiring pharmacy benefit managers to disclose what they earn from negotiating drug prices for employer health plans, Axios reports. These companies negotiate prescription drug benefits for employers and workers on their plans. They will also have to reveal what they pay for drugs and what drugmakers pay them, according to The Washington Post.
Axios reports that managers must disclose their earnings every six months or when an agreement is renewed or extended. The disclosures include payments from drugmakers and instances of “spread pricing,” when a health plan pays more for a drug than the manager reimburses the pharmacy. Managers must also identify cases in which a drug’s total cost is less than a patient’s copayment. Plans can audit them at least once a year, and managers must explain earnings that exceed their estimates by 5% or more.
The rule takes effect in July for self-insured group plans with more than 100 participants that pay their own health claims, Axios reports. It covers fewer plans than originally envisioned.
Whether the disclosures will lower costs is disputed. Labor Secretary Keith Sonderling said in a statement cited by The Washington Post that the rule will help employers negotiate better deals and lower drug prices. According to Axios, the Pharmaceutical Care Management Association, a trade group for pharmacy benefit managers, said the rule could instead raise patient costs and reduce competition by adding another reporting system.
The rule does not directly restrict managers’ pricing, spread-pricing compensation or retention of manufacturer rebates, Raymond James analyst Chris Meekins wrote in a note cited by Axios. His question is whether greater visibility will reduce what managers keep or simply change how they charge it.
Comments